Core Viewpoint - Beckman Coulter Life Sciences is celebrating its 90th anniversary in 2025, emphasizing its commitment to innovation and local market development in China, which has become a significant contributor to its global strategy [1][19]. Group 1: Innovation and Historical Development - The company has maintained a focus on solving industry pain points from its inception, starting with the invention of the commercial pH meter in 1935 by Dr. Beckman [3][4]. - The merger of Beckman and Coulter in 1997 expanded the company's technological capabilities across life sciences and clinical diagnostics [4]. - The introduction of the CytoFLEX flow cytometer, developed from local market insights, exemplifies how China serves as both a crucial market and an innovation source [7][9]. Group 2: Localization Strategy - Beckman Coulter Life Sciences has established a comprehensive local value chain in China, including sales, service, manufacturing, and R&D, since the early days of reform and opening up [9][12]. - The Suzhou factory not only serves as a production base but also as a global R&D innovation hub, demonstrating a closed-loop of "China demand driving global innovation" [9][12]. - The company emphasizes that localization does not mean lowering standards but achieving "China manufacturing, global quality" through strict adherence to international quality management systems [12][17]. Group 3: Future Outlook and Ecosystem Development - The company plans to focus on technological foresight and ecosystem collaboration, investing in cutting-edge fields like exosome research and synthetic biology [15][19]. - Beckman Coulter aims to be a trusted partner by providing not only equipment but also training and academic exchanges to elevate industry standards [15][17]. - The balance between globalization and localization is highlighted through increased production capacity in China, which supports both local and global markets [17][19].